You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations
SharePoint
Sign In
Follow
It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Home
About
CRISM
OCRINT
Nominated Principal Investigators
Our Team
Events
Research Projects
COVID-19 Research Projects
OPTIMA
Section 56 Consultation
Follow-Up Study of Federal Inmates on Opioid Agonist Treatment in Ontario
Ontario-Based Residential Treatment Environmental Scan
Inequities in Access to Opioid Agonist Treatment (OAT) Take Home Doses (THD)
COVID-19 Vaccine Confidence Among PWUD
Sudbury Supervised Consumption Site Evaluation
BC Decriminalization Policy Evaluation
Nominal Group Technique Expert Committee
Advisory Board
Logic Model
People Who Use Drugs (PWUD) Qualitative Study
Qualitative Police Study
Quantitative Health and Police Data Analyses
Impact on General Public
Health Service Systems
Economic Impacts
Knowledge Validity and Triangulation
Decriminalization Evaluation Publications and Reports
Research Team
PWLE National Working Group
Cannabis Projects
Implementation Science Program
Naloxone Distribution
Detoxification and Withdrawal Management
Corrections Projects
Guidance Documents
Currently selected
COVID-19 Rapid Guidance
Opioid Use Disorder
Injectable OAT
Lower Risk Cannabis Use Guidelines
Supervised Consumption Services
Take-home Naloxone Distribution
Demonstration Projects
Best Practice Document on Harm Reduction Programs for PWUD
Chronic Disease Self-management Experiences among Marginalized PWUD
Impacts of Overdose Study
It Takes a Village
Best Practices in Buprenorphine/Naloxone Initiation in Provincial Correctional Facilities
Asset Mapping of Substance Use Prevention and Intervention Programs and Services
Surviving Opioid Overdose with Naloxone Education and Resuscitation
Integrating Access to Anti-Craving Medications for Adult Women with SUD
Northern Ontario Drug Use and Service Needs Assessment (NODUS)
Youth Substance Use Service Provider Study
Identifying Service Needs among PWUD
Publications and Reports
Academic Journal Articles
Contact Us
Reports
Knowledge Translation Products
NATIONAL OPIOID USE DISORDER GUIDELINE
Page Content
CRISM developed the first Canadian guideline for managing opioid use disorders. The guideline lays out the optimal strategies for the treatment of opioid addiction and recommends opioid agonist treatment with buprenorphine-naloxone as the preferred first-line treatment.
GUIDELINE (English)
GUIDELINE (French)
RECOMMENDATIONS AT A GLANCE
RECOMMENDATIONS CLINIQUES
A synopsis of the guideline was published in the Canadian Medical Association Journal (March 5, 2018). You can access it
here
, or d
ownload the
PDF
.
CMAJ
also produced a podcast, which you can listen to
here
.
SUPPLEMENTAL MATERIALS:
Did you know? Buprenorphine/Naloxone
Did you know? Slow-release oral morphine
Withdrawal Management Safety Bulletin